Peer-influenced content. Sources you trust. No registration required. This is HCN.
Source: BMC Pulmonary MedicineFindings: IPF patients who switched from one antifibrotic therapy to the alternative — whether from pirfenidone (Esbriet) to nintedanib (Ofev, Vargatef) or the other way around – had improved survival. This observation held true whether the reason for switch was disease progress or tolerance issues.Design: Multi-center retrospective cohort study; 262 patients
Allergy & Immunology August 17th 2021
The investigational agent – known as REGEN-COV (casirivimab and imdevimab) – was previously granted the Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19. Now, those who are at high risk for progression to severe COVID-19, including hospitalization or death, have an option.
Allergy & Immunology August 9th 2021
MedPage Today
Is the debate over? The Morbidity and Mortality Weekly Report (MMWR) discusses this case-control study, which showed that people are twice as likely to get infected again if they are unvaccinated. The debate over vaccinations has been bitter so far, but the results present comforting news for those vaccinated but worried about the fast-spreading Delta variant…while alerting the unvaccinated of their much higher potential to become infected again.
Healthgrades for Professionals
According to a study of 135,000 doctors by Doximity, male physicians made, on average, 28% more than females in 2020, a 3% increase from the 2019 numbers. The survey, along with Medscape’s poll in 2021 that showed male specialist physicians overall making 33% more than females, points to a few other large gender pay gaps, as well as some in which women doctors make salaries closer to those of men.
Allergy & Immunology July 19th 2021
Johns Hopkins Medicine
Despite many doing their research and learning all they can about the COVID-19 vaccine, patients may still come to you for more help. To assist your patients with their questions about the COVID-19 vaccine, here are 12 facts and insights shared by Sherita Golden, MD, MHS, chief diversity officer at Johns Hopkins Medicine, who specializes in diabetes, heart conditions and patterns of disease in diverse communities.
Family Medicine/General Practice July 19th 2021
According to Daniel A. Nation, PhD, associate professor of psychological science at University of California, Irvine: “Studies of angiotensin II receptor blockers and ACE inhibitors have suggested these medicines may confer the greatest benefit to long-term cognition, while other studies have shown the benefits of calcium channel blockers and diuretics on reducing dementia risk.”
Cardiology July 13th 2021